Jazz Pharmaceuticals
JAZZ
408 hedge funds and large institutions have $5.01B invested in Jazz Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 124 increasing their positions, 172 reducing their positions, and 85 closing their positions.
2.66% less ownership
Funds ownership: 91.97% → 89.31% (-2.7%)
9% less funds holding
Funds holding: 446 → 408 (-38)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
28% less repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 172
33% less call options, than puts
Call options by funds: $18.3M | Put options by funds: $27.2M
35% less capital invested
Capital invested by funds: $7.76B → $5.01B (-$2.76B)
39% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.2M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$50.1M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$41.6M |
| 4 |
Holocene Advisors
New York
|
+$38.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$57.9M |
| 2 |
Bank of New York Mellon
New York
|
-$53.2M |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$43.1M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$35.7M |
| 5 |
D.E. Shaw & Co
New York
|
-$33M |
JAZZ Hedge Fund Activity: Q1 2020 in Review
408 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2020, worth a combined $5.01B — down 35% from $7.76B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of JAZZ and 52 opened new positions — a net loss of 33 holders — while 172 trimmed existing stakes and 124 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $65.2M. The largest seller was Arrowstreet Capital, cutting an estimated $57.9M.
- 408 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2020, down from 446 in Q4 2019.
- Funds reported $5.01B of Jazz Pharmaceuticals stock for Q1 2020, down 35% quarter-over-quarter.
- 52 funds opened new Jazz Pharmaceuticals positions in Q1 2020 and 85 closed out, a net change of -33 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2020 was T. Rowe Price Associates, an estimated $65.2M added.
- The largest Jazz Pharmaceuticals seller in Q1 2020 was Arrowstreet Capital, an estimated $57.9M sold.
Based on aggregated 13F filings for Q1 2020.